|
1
|
Hwang SY, Danpanichkul P, Agopian V, Mehta
N, Parikh ND, Abou-Alfa GK, Singal AG and Yang JD: Hepatocellular
carcinoma: Updates on epidemiology, surveillance, diagnosis and
treatment. Clin Mol Hepatol. 31 (Suppl):S228–S254. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mak LY, Liu K, Chirapongsathorn S, Yew KC,
Tamaki N, Rajaram RB, Panlilio MT, Lui R, Lee HW, Lai JC, et al:
Liver diseases and hepatocellular carcinoma in the Asia-Pacific
region: Burden, trends, challenges and future directions. Nat Rev
Gastroenterol Hepatol. 21:834–851. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang A, Yang XR, Chung WY, Dennison AR
and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal
Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim H, Park J and Roh SH: The structural
basis of eukaryotic chaperonin TRiC/CCT: Action and folding. Mol
Cells. 47:1000122024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gruber R and Horovitz A: Allosteric
mechanisms in chaperonin machines. Chem Rev. 116:6588–6606. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Date Y, Matsuura A and Itakura E:
Disruption of actin dynamics induces autophagy of the eukaryotic
chaperonin TRiC/CCT. Cell Death Discov. 8:372022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gestaut D, Zhao Y, Park J, Ma B, Leitner
A, Collier M, Pintilie G, Roh SH, Chiu W and Frydman J: Structural
visualization of the tubulin folding pathway directed by human
chaperonin TRiC/CCT. Cell. 185:4770–4787.e20. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu HH, Liu QH, Meng QN, Zhang LJ, Ju SW,
Lang JH, Zhu DH, Chen YX, Aishan N, Ouyang XX, et al:
CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from
ferroptosis by inhibiting iron endocytosis. J Exp Clin Canc Res.
43:2452024. View Article : Google Scholar
|
|
9
|
Li F, Liu CS, Wu P, Ling AS, Pan Q and Li
XN: CCT4 suppression inhibits tumor growth in hepatocellular
carcinoma by interacting with Cdc20. Chin Med J (Engl).
134:2721–2729. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang XD, Wang XX, Cheng C, Cai J, He S,
Wang H, Liu F, Zhu CL, Ding ZM, Huang XT, et al: Chaperonin
containing TCP1, subunit 8 (CCT8) is upregulated in hepatocellular
carcinoma and promotes HCC proliferation. Apmis. 122:1070–1079.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv W, Shi L, Pan J and Wang S:
Comprehensive prognostic and immunological analysis of CCT2 in
pan-cancer. Front Oncol. 12:9869902022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Showalter AE, Martini AC, Nierenberg D,
Hosang K, Fahmi NA, Gopalan P, Khaled AS, Zhang W and Khaled AR:
Investigating Chaperonin-containing TCP-1 subunit 2 as an essential
component of the chaperonin complex for tumorigenesis. Sci Rep.
10:7982020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carr AC, Khaled AS, Bassiouni R, Flores O,
Nierenberg D, Bhatti H, Vishnubhotla P, Manuel JP, Santra S and
Khaled AR: Targeting chaperonin containing TCP1 (CCT) as a
molecular therapeutic for small cell lung cancer. Oncotarget.
8:110273–110288. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Dong Z and Liu K: Unraveling the
complexity of STAT3 in cancer: Molecular understanding and drug
discovery. J Exp Clin Cancer Res. 43:232024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berkley K, Zalejski J and Sharma A:
Targeting STAT3 for cancer therapy: Focusing on Y705, S727, or dual
inhibition? Cancers (Basel). 17:7552025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Zeng X, Huang J, Ma S, Li K, Yang S,
Naz W, Yousaf T, Yuan S, Liu Y, et al: Dual-specificity
tyrosine-regulated kinase 4 modulates the STAT3-FOS signaling axis
to inhibit hepatitis B virus replication via autophagy. Int J Biol
Sci. 21:2415–2429. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tulahong A, Xu X, Zhou T, Ruze R, Yuan Z,
Qiao P, Jiang T, Aji T and Shao Y: Empagliflozin alleviates hepatic
ischemia-reperfusion injury by inhibiting c-Myc through the
JAK1-STAT3 signaling pathway. Int Immunopharmacol. 165:1155082025.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nian F, Chen Y, Chen J, Jiang Q, Meng F,
Chen Z, Lu X, Shen X and Li Y: Carpaine alleviates NASH-related
fibrosis by targeting Nid1 to inhibit IL-6/JAK/STAT3 signaling and
macrophage M1 polarization. Int J Biol Macromol. 337:1494512025.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashemi M, Sabouni E, Rahmanian P,
Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M,
Mirzaei S, Hushmandi K, et al: Deciphering STAT3 signaling
potential in hepatocellular carcinoma: Tumorigenesis, treatment
resistance, and pharmacological significance. Cell Mol Biol Lett.
28:332023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Ma CN, Li YM, Liang YR, Chen T,
Han DW, Luo D, Zhang N, Zhao WJ, Wang LJ, et al: Trim21-mediated
CCT2 ubiquitination suppresses malignant progression and promotes
CD4+T cell activation in breast cancer. Cell Death Dis.
15:5422024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vallin J, Córdoba-Beldad CM and Grantham
J: Sequestration of the transcription factor STAT3 by the molecular
chaperone CCT: A potential mechanism for modulation of STAT3
phosphorylation. J Mol Biol. 433:1669582021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cancer Genome Atlas Research Network.
Electronic address, . simplewheeler@bcm.edu and Cancer
Genome Atlas Research Network: Comprehensive and integrative
genomic characterization of hepatocellular carcinoma. Cell.
169:1327–1341.e23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujimoto A, Furuta M, Totoki Y, Tsunoda T,
Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et
al: Whole-genome mutational landscape and characterization of
noncoding and structural mutations in liver cancer. Nat Genet.
48:500–509. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao Q, Zhu H, Dong L, Shi W, Chen R, Song
Z, Huang C, Li J, Dong X, Zhou Y, et al: Integrated Proteogenomic
characterization of HBV-related hepatocellular carcinoma. Cell.
179:561–577. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang Z, Wu Y, Miao Y, Deng K, Yang F, Xu
S, Wang Y, You R, Zhang L, Fan Y, et al: HCCDB v2.0: Decompose
expression variations by Single-cell RNA-seq and spatial
Transcriptomics in HCC. Genomics Proteomics Bioinformatics.
22:qzae0112024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C, Cheng X and Jiang Y:
Deuterium-depleted water inhibits the malignant progression of
colorectal cancer cells by modulating oxidative stress. Oncol Rep.
53:702025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li C, Miao R, Zhang J, Qu K and Liu C:
Long non-coding RNA KCNQ1OT1 mediates the growth of hepatocellular
carcinoma by functioning as a competing endogenous RNA of miR-504.
Int J Oncol. 52:1603–1612. 2018.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ranjbar R, Behzadi P and Mammina C:
Respiratory tularemia: Francisella tularensis and microarray probe
designing. Open Microbiol J. 10:176–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M,
Liu Y and Li Y, Lu L, Liu Y and Li Y: Lenvatinib in hepatocellular
carcinoma: Resistance mechanisms and strategies for improved
efficacy. Liver Int. 44:1808–1831. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Macario AJL and Conway de Macario E:
Chaperonins in cancer: Expression, function, and migration in
extracellular vesicles. Semin Cancer Biol. 86:26–35. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grantham J: The molecular chaperone
CCT/TRiC: An essential component of proteostasis and a potential
modulator of protein aggregation. Front Genet. 11:1722020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zou Q, Yang ZL, Yuan Y, Li JH, Liang LF,
Zeng GX and Chen SL: Clinicopathological features and CCT2 and
PDIA2 expression in gallbladder squamous/adenosquamous carcinoma
and gallbladder adenocarcinoma. World J Surg Oncol. 11:1432013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Q, Qi Y, Kong X, Wang X, Zhang W, Zhai
J, Yang Y, Fang Y and Wang J: Molecular and clinical
characterization of CCT2 expression and prognosis via Large-scale
transcriptome profile of breast cancer. Front Oncol. 11:6144972021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma X, Qiu SP, Tang X, Song QY, Wang PC,
Wang JW, Xia QC, Wang ZJ, Zhao QH and Lu M: TSPAN31 regulates the
proliferation, migration, and apoptosis of gastric cancer cells
through the METTL1/CCT2 pathway. Transl Oncol. 20:1014232022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park SH, Jeong S, Kim BR, Jeong YA, Kim
JL, Na YJ, Jo MJ, Yun HK, Kim DY, Kim BG, et al: Activating CCT2
triggers Gli-1 activation during hypoxic condition in colorectal
cancer. Oncogene. 39:136–150. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li YF, Su S, Luo Y, Wei C, He J, Song LD,
Han K, Wang J, Gan X and Wang DL: Widespread activation and
critical role of EMT and stemness in the neuroendocrine
differentiation of prostate cancer (Review). Oncol Rep. 54:1092025.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ham A, Cho MH, Won HS, Jo J and Lee KE:
β-catenin blockers enhance the effect of CDK4/6 inhibitors on
stemness and proliferation suppression in endocrine-resistant
breast cancer cells. Oncol Rep. 48:1302022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kasembeli M, Lau WCY, Roh SH, Eckols TK,
Frydman J, Chiu W and Tweardy DJ: Modulation of STAT3 folding and
function by TRiC/CCT Chaperonin. PLoS Biol. 12:e10018442014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu DN, Zeng JZ, Sun HM, Pan YL, Yang CC
and Lu YD: Chaperonin containing TCP1 subunit 3 (CCT3) promotes
cisplatin resistance of lung adenocarcinoma cells through targeting
the Janus kinase 2/signal transducers and activators of
transcription 3 (JAK2/STAT3) Pathway. Bioengineered. 12:7335–7347.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang G, Zhang M, Meng P, Long CB, Luo XD,
Yang XW, Wang YF, Zhang ZY, Mwangi J, Kamau PM, et al: Anticarin-β
shows a promising anti-osteosarcoma effect by specifically
inhibiting CCT4 to impair proteostasis. Acta Pharm Sin B.
12:2268–2279. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao FH, Yao Z, Li YQ, Zhao WB, Sun YF,
Yang XB, Zhao ZM, Huang B, Wang J, Li XA, et al: Targeting the
molecular chaperone CCT2 inhibits GBM progression by influencing
KRAS stability. Cancer Lett. 590:2168442024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen JY, Hu Q, Zhou CH and Jin DW: CCT2
prevented β-catenin proteasomal degradation to sustain cancer stem
cell traits and promote tumor progression in epithelial ovarian
cancer. Mol Biol Rep. 51:542024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu WP, Lin RZ, Zhu CM, Chen YXZ, Gao QA
and Zhong JJ: CCT2 regulates ZEB1-induced EMT gene transcription to
promote the metastasis and tumorigenesis of papillary thyroid
carcinoma. Discov Med. 36:1819–1830. 2024. View Article : Google Scholar : PubMed/NCBI
|
